Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard B S Roden

Showing results (11-20 of 136) with videos related to

Pageof 14
Sort By:
Statistics in Medicine|October 29, 2018
A Bayesian design for phase I cancer therapeutic vaccine trialsChenguang Wang, Gary L Rosner, Richard B S Roden
Human Pathology|August 7, 2004
Vaccination to prevent and treat cervical cancerRichard B S Roden, Morris Ling, T-C Wu
Proteomics|November 25, 2011
Identification of glycoproteins associated with different histological subtypes of ovarian tumors using quantitative glycoproteomicsYuan Tian, Zhihao Yao, Richard B S Roden, et al.
Current Opinion in Investigational Drugs (London, England : 2000)|January 15, 2005
Human papillomavirus vaccines for the prevention and treatment of cervical cancerTodd T Tomson, Richard B S Roden, T-C Wu
Vaccine|May 4, 2010
Vaccination with multimeric L2 fusion protein and L1 VLP or capsomeres to broaden protection against HPV infectionSubhashini Jagu, Kihyuck Kwak, Robert L Garcea, et al.
Journal of Clinical Medicine|April 3, 2021
RG1-VLP and Other L2-Based, Broad-Spectrum HPV Vaccine CandidatesBettina Huber, Joshua Weiyuan Wang, Richard B S Roden, et al.
Immunology and Cell Biology|May 8, 2009
Developing vaccines against minor capsid antigen L2 to prevent papillomavirus infectionBalasubramanyam Karanam, Subhashini Jagu, Warner K Huh, et al.
Journal of Virology|November 27, 2004
The positively charged termini of L2 minor capsid protein required for bovine papillomavirus infection function separately in nuclear import and DNA bindingAlyson Fay, William H Yutzy, Richard B S Roden, et al.
Expert Review of Vaccines|February 23, 2016
Progress and prospects for L2-based human papillomavirus vaccinesRosie T Jiang, Christina Schellenbacher, Bryce Chackerian, et al.
The Journal of Biological Chemistry|February 25, 2016
The Proteasome Ubiquitin Receptor hRpn13 and Its Interacting Deubiquitinating Enzyme Uch37 Are Required for Proper Cell Cycle ProgressionLeah Randles, Ravi K Anchoori, Richard B S Roden, et al.
Pageof 14

Showing results (11-20 of 136) with videos related to

Sort By:
Pageof 14
Statistics in Medicine|October 29, 2018
A Bayesian design for phase I cancer therapeutic vaccine trialsChenguang Wang, Gary L Rosner, Richard B S Roden
Human Pathology|August 7, 2004
Vaccination to prevent and treat cervical cancerRichard B S Roden, Morris Ling, T-C Wu
Proteomics|November 25, 2011
Identification of glycoproteins associated with different histological subtypes of ovarian tumors using quantitative glycoproteomicsYuan Tian, Zhihao Yao, Richard B S Roden, et al.
Current Opinion in Investigational Drugs (London, England : 2000)|January 15, 2005
Human papillomavirus vaccines for the prevention and treatment of cervical cancerTodd T Tomson, Richard B S Roden, T-C Wu
Vaccine|May 4, 2010
Vaccination with multimeric L2 fusion protein and L1 VLP or capsomeres to broaden protection against HPV infectionSubhashini Jagu, Kihyuck Kwak, Robert L Garcea, et al.
Journal of Clinical Medicine|April 3, 2021
RG1-VLP and Other L2-Based, Broad-Spectrum HPV Vaccine CandidatesBettina Huber, Joshua Weiyuan Wang, Richard B S Roden, et al.
Immunology and Cell Biology|May 8, 2009
Developing vaccines against minor capsid antigen L2 to prevent papillomavirus infectionBalasubramanyam Karanam, Subhashini Jagu, Warner K Huh, et al.
Journal of Virology|November 27, 2004
The positively charged termini of L2 minor capsid protein required for bovine papillomavirus infection function separately in nuclear import and DNA bindingAlyson Fay, William H Yutzy, Richard B S Roden, et al.
Expert Review of Vaccines|February 23, 2016
Progress and prospects for L2-based human papillomavirus vaccinesRosie T Jiang, Christina Schellenbacher, Bryce Chackerian, et al.
The Journal of Biological Chemistry|February 25, 2016
The Proteasome Ubiquitin Receptor hRpn13 and Its Interacting Deubiquitinating Enzyme Uch37 Are Required for Proper Cell Cycle ProgressionLeah Randles, Ravi K Anchoori, Richard B S Roden, et al.
Pageof 14